Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023)

Diabetes Metab Res Rev. 2024 Mar;40(3):e3646. doi: 10.1002/dmrr.3646. Epub 2023 May 23.

Abstract

The International Working Group on the Diabetic Foot (IWGDF) has published evidence-based guidelines on the prevention and management of diabetic foot disease since 1999. This is the first guideline on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes published by the IWGDF. We followed the GRADE Methodology to devise clinical questions in the PACO (Population, Assessment, Comparison, Outcome) and PICO (Population, Intervention, Comparison, Outcome) format, conducted a systematic review of the medical literature, and developed recommendations with the rationale. The recommendations are based on the evidence from our systematic review, expert opinion when evidence was not available, and also taking into account weighing of the benefits and harms, patient preferences, feasibility and applicability, and costs related to an intervention. We here present the 2023 Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus and also suggest key future topics of research.

Keywords: Charcot foot; Charcot neuro-osteoarthropathy; Charcot neuroarthropathy; Charcot osteoarthropathy; diabetic foot; guidelines.

Publication types

  • Systematic Review

MeSH terms

  • Arthropathy, Neurogenic* / complications
  • Arthropathy, Neurogenic* / diagnosis
  • Diabetes Mellitus*
  • Diabetic Foot* / diagnosis
  • Diabetic Foot* / etiology
  • Diabetic Foot* / therapy
  • Humans